-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Worldwide, due to the use of HPV vaccine, the incidence of cervical cancer is reduced by about 1% to 1.
In recent years, as a new treatment model, immunotherapy has made exciting progress in a variety of malignant tumors, and has also brought new hope to patients with recurrent metastatic cervical cancer, and has changed or is changing the treatment pattern
01
The HLX10-011-CC201 study, led by Professor Wu Lingying of the Cancer Hospital of the Chinese Academy of Medical Sciences, was selected for the 2022 SGO Conference Oral Report
02
At SGO 2022, Jyoti Mayadev reported a Phase I NRG-GY017 study in which 40 patients with stage IB to IVA with paraortic lymph node metastasis or stage II.
03
The 2022 ASCO Conference reported on the interim results of the Phase II innovaTV 205 study for the treatment of recurrent or metastatic cervical cancer, and the results of second-line/third-line TV+ pambolizumab and first-line TV+ carboplatin were disclosed for the
first time at this meeting.
The dose expansion cohort of the novel antibody-coupled drug Tisotumab vedotin (TV) in combination with pambolizumab or carboplatin for r/mCC showed strong and durable antitumor activity and tolerable safety, with an objective response rate (ORR) of 40.
6% (13/32, 5 CR, 8 PR) in the first-line TV + pambolizumab group and a disease control rate (DCR) of 84.
4%; The median PFS was 5.
3 months, and the median duration of remission (DOR) and OS were not achieved, and the incidence of adverse events (TEAE) during treatment of ≥ 3 was 67%, with the most common being anemia (12%), fatigue (9%), and hypokalemia (9%)
.
In patients with recurrent metastatic cervical cancer, the dose-expanding cohort of TV in combination with Pemvro or Carbo showed encouraging and long-lasting antitumor activity, safety, and tolerability
.
04
Professor Zhang Yunyan concluded
Poor prognosis for patients with advanced and recurrent metastatic cervical cancer has always been a formidable challenge for clinicians
.
Many studies such as immunization combined chemoradiotherapy, immune combined anti-vascular therapy, and double exemption combination therapy are being actively carried out, and breakthroughs have been made in treatment, with good safety and feasibility
.
At present, the task of medical research is to do more translational work in the immune microenvironment, and focus on prediction and prognosis-specific biomarkers to solve problems such as low remission rate and more clinical adverse reactions
.
Develop a more complete treatment strategy of immune combined with radiotherapy and chemotherapy to benefit patients
with advanced cervical cancer.
Expert Profiles
Professor Zhang Yunyan
Harbin Medical University Affiliated Cancer Hospital
Director of gynecological radiotherapy ward Chief Physician Level II Professor Doctoral Supervisor
Famous doctor in Longjiang
Standing Committee Member of Brachytherapy Professional Committee of Chinese Anti-Cancer Association
Member of the Brachytherapy Group of the Radiotherapy Committee of the Chinese Medical Association
Member of gynecological tumor radiotherapy group of Chinese Medical Doctor Association
Member of the CSCO Gynecologic Oncology Committee
Member of the Gynecologic Oncology Group of the Precision Medicine and Tumor MDT Committee of the Chinese Society of Research Hospitals
Standing Director of Heilongjiang Anti-Cancer Association
Chairman of the Gynecologic Tumor Radiation Therapy Professional Committee of Heilongjiang Medical Doctor Association
Vice Chairman of gynecological oncology branch of Heilongjiang Medical Association
Standing Committee Member of Obstetrics and Gynecology Professional Committee of Heilongjiang Medical Doctor Association
Standing Committee Member of Anti-Cancer Drugs Professional Committee of Heilongjiang Anti-Cancer Association
Member of obstetrics and gynecology branch of Heilongjiang Medical Association
Member of the Tumor Radiation Therapy Professional Committee of Heilongjiang Medical Association
He studied
at the University of Pittsburgh and MD Anderson Cancer Center.
He presided over 1 key project of the National Natural Area Joint Fund and 2 projects
on the national natural area.
1 provincial natural key project
.
1 provincial key research and development project
.
He has won 1 second prize for scientific and technological progress of the provincial government and 1 first prize for scientific and technological progress of the provincial health department
.
The provincial health department medical new technology first prize 3.
He has published more than 20 SCI papers
.
Participated in the compilation of 5 planning textbooks of the Ministry of
Health.
He specializes in radiation therapy and comprehensive treatment
of gynecological tumors such as cervical cancer and endometrial cancer.
The province took the lead in carrying out three-dimensional after-loading and insertion therapy
.
Master the most advanced in vitro radiotherapy technology including TOMO, VMAT and other treatment techniques
.
He has rich clinical experience
in the comprehensive treatment of gynecological tumors such as advanced and recurrent cervical cancer (immunotherapy and targeted therapy).
Typography: Hu Haiyan
Editor: Lina Wang
Audit: Qin Miao
8 special trains from 4 places in the north to Guangzhou and Hangzhou have set sail! The train will carry 1220 public welfare touring exhibition posters including 22 academicians/ Chinese medicine masters/ national famous Chinese medicine doctors, 145 hospital management experts, and 1582 medical elites, including academician Zhong Nanshan, for a one-month tour exhibition, which will "close contact" with more than 200 million passengers! At the same time, the total video of the poster will be broadcast in turn on the 13,000 TVs covering the subway and platforms on the Beijing 1, 2, 5, 8, 13 and Batong lines every day, and it is expected that more than 100 million views will be viewed!
Highlights of the public welfare touring exhibition activities:
Tribute to Chinese Physicians' Day • Healthy China You and I Walk Together 68 | Li Shengping: Standing at the commanding heights of pancreatic and bile surgery, boosting the hospital to build a world-class cancer center
Tribute to Chinese Doctors' Day • Healthy China You and I Walk together | Yuan Guanghai: the beating on the fingertips, accompanying him on the medical road
Tribute to Chinese Physicians' Day Health China You and I Walk Together 66 | Professor Wang Yan's MDT team: helping advanced lung cancer patients out of the quagmire of despair
Tribute to Chinese Physicians' Day Health China You and I walk together 65| Professor Xue Wei: Don't just be a surgeon, treat patients as "people"!
Tribute to Chinese Physicians' Day • Healthy China You and I Walk together 64| Zhang Gejun: High standards, strict requirements, promote structural heart disease technology innovation
The power to move the industry forward! The 7th Medical Scientist Summit 2022 conference report is coming!
In 2022, the "Physician's Daily" is hotly subscribed to the !!! Millions of doctors are watching.
.
.
For more information, please click here:
Consensus release | The expert consensus on the prevention and treatment of traditional Chinese medicine infected with the new coronavirus Aomi Kerong variant strain was released
| Zeng Xiaofeng, the 7th Annual Meeting of Medical Scientists (14), shared the story of Professor Zhang Naizheng, the father of Rheumatology in China: a generation of grandmasters with lofty aspirations who have the world in mind and lofty aspirations
"Physician's Daily" submission public mailbox: yishibao2017@163.
com
【Note】Some of the pictures come from the network and WeChat circle of friends, if there is infringement, please contact to delete, thank you! Tel:010-58302828-6808
Currently 1,130,000+ doctors have followed to join us